Henning Carstens

Dr. Henning Carstens

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HCHenning Carstens
Henning Carstens
KKKatharina Kalka
Katharina Kalka
RVRabea Verhaegh
Rabea Verhaegh
FSFabian Schumacher
Fabian Schumacher
MSMatthias Soddemann
Matthias Soddemann
MKMarkus Kamler
Markus Kamler
Background: Ex-vivo lung perfusion (EVLP) is a save way to verify performance of donor lungs prior to implantation. A major problem of lung transplantation is a donor-to-recipient-transmission of bacterial cultures. Thus, a broadspectrum anti-infective treatment with sphingosine in EVLP might be a novel way to prevent such infections. Sphingosine inhalation might provide a reliable anti-infective treatment option in EVLP. Here, antimicrobial potency of inhalative sphingosine in an infection EVLP model was tested. Methods: A 3-hour EVLP run using pig lungs was performed. Bacterial infection was initiated 1-hour before sphingosine inhalation. Biopsies were obtained 60 and 120 min after infection with Pseudomonas aeruginosa. Aliquots of broncho-alveolar lavage (BAL) before and after inhalation of sphingosine were plated and counted, tissue samples were fixed in paraformaldehyde, embedded in paraffin and sectioned. Immunostainings were performed. Results: Sphingosine inhalation in the setting of EVLP rapidly resulted in a 6-fold decrease of P. aeruginosa CFU in the lung (p = 0.016). We did not observe any negative side effects of sphingosine. Conclusion: Inhalation of sphingosine induced a significant decrease of Pseudomonas aeruginosa at the epithelial layer of tracheal and bronchial cells. The inhalation has no local side effects in ex-vivo perfused and ventilated pig lungs.

20 September 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HCHenning Carstens
Henning Carstens
KKKatharina Kalka
Katharina Kalka
RVRabea Verhaegh
Rabea Verhaegh
FSFabian Schumacher
Fabian Schumacher
MSMatthias Soddemann
Matthias Soddemann
MKMarkus Kamler
Markus Kamler
Ex-vivo lung perfusion (EVLP) systems like XVIVO are more and more common in the setting of lung transplantation, since marginal donor-lungs can easily be subjected to a performance test or be treated with corticosteroids or antibiotics in high dose regimes. Donor lungs are frequently positive in bronchoalveolar lavage (BAL) bacterial cultures (46–89%) which leads to a donor-to-recipient transmission and after a higher risk of lung infection with reduced posttransplant outcome. We have previously shown that sphingosine very efficiently kills a variety of pathogens, including Pseudomonas aeruginosa, Staphylococcus aureus and epidermidis, Escherichia coli or Haemophilus influenzae. Thus, sphingosine could be a new treatment option with broadspectrum antiinfective potential, which may improve outcome after lung transplantation when administered prior to lung re-implantation. Here, we tested whether sphingosine has any adverse effects in the respiratory tract when applied into isolated ventilated and perfused lungs. A 4-h EVLP run using minipig lungs was performed. Functional parameters as well as perfusate measurements where obtained. Biopsies were obtained 30 min and 150 min after inhalation of sphingosine. Tissue samples were fixed in paraformaldehyde, embedded in paraffin and sectioned. Hemalaun, TUNEL as well as stainings with Cy3-coupled anti-sphingosine or anti-ceramide antibodies were implemented. We demonstrate that tube-inhalation of sphingosine into ex-vivo perfused and ventilated minipig lungs results in increased levels of sphingosine in the luminal membrane of bronchi and the trachea without morphological side effects up to very high doses of sphingosine. Sphingosine also did not affect functional lung performance. In summary, the inhalation of sphingosine results in an increase of sphingosine concentrations in the luminal plasma membrane of tracheal and bronchial epithelial cells. The inhalation has no local side effects in ex-vivo perfused and ventilated minipig lungs.

1 October 2024 in Interdisciplinary CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
HCHenning Carstens
Henning Carstens
DBDaniel Biermann
Daniel Biermann
JSJörg Sachweh
Jörg Sachweh
MMMartin Munz
Martin Munz
IHIda Hüners
Ida Hüners
MHMichael Hübler
Michael Hübler
Minimally invasive surgical closure of atrial septal defects is gaining widespread acceptance and can be performed via a right midaxillary thoracotomy. In addition, the procedure can be performed in ischaemic cardiac arrest or fibrillation with a core body temperature between 34°C and 36°C. We present our single-centre results of paediatric patients who underwent surgical atrial septal defect II closure via lateral thoracotomy. Retrospective analysis. Patients were divided into a cardiac arrest group and a cardiac fibrillation group. All procedures were performed via right midaxillary thoracotomy through a single incision without side ports. All 37 consecutive patients between March 2019 and August 2022 (median age 3 years; percentile 25th: 2; 75th: 5 years) in both groups were free of mortality and postoperative morbidity such as haemodynamically relevant residual shunt or malignant arrhythmias. Cardiopulmonary bypass time was significantly shorter in the fibrillation group (mean: 34.7 min vs 52.6 min, P = 0.01), and all patients were weaned off the ventilator immediately postoperatively. Length of the intensive care unit stay was not different between the 2 groups. Postoperative hospital stay was significantly longer in patients with cardiac arrest (mean: 5.6 days vs 4.9 days, P = 0.04). Postoperative laboratory parameters did not differ between the 2 groups. All patients were discharged with normal left ventricular function and normalized cardiac enzymes. Minimally invasive closure of an atrial septal defect during atrial fibrillation is a safe procedure with results comparable to those of an induced cardiac arrest procedure.

1 January 2024 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Open access
PDF file
MMMarlene Müller
Marlene Müller
DBDaniel Biermann
Daniel Biermann
MRMiriam Mkanyika Righa
Miriam Mkanyika Righa
HCHenning Carstens
Henning Carstens
RKRainer Gerhard Kozlik-Feldmann
Rainer Gerhard Kozlik-Feldmann
JSJörg Siegmar Sachweh
Jörg Siegmar Sachweh
Background In patients with tetralogy of Fallot (ToF) or ToF-like anatomy, factors possibly impacting the longevity of biological valves in the pulmonary position were investigated. Method Between 1997 and 2017, 79 consecutive hospital survivors with a median age of 8.7 years (range: 0.2–56.1 years; interquartile range [IQR]: 14.8 years) with ToF or ToF-like anatomy underwent surgical implantation of Contegra (n = 34), Hancock (n = 23), Perimount (n = 9), pulmonary homograft (n = 9), and miscellaneous (n = 4) conduits. The median internal graft diameter was 19 mm (range: 11–29 mm; IQR: 8 mm) which refers to a median z-score of 0.6 standard deviation (SD) (range: −1.8 to 4.0 SD; IQR: 2.1 SD). Results The median time of follow-up was 9.4 years (range: 1.1–18.8 years; IQR: 6.0 years). Thirty-nine patients (49%) underwent surgical (n = 32) or interventional (n = 7) pulmonary valve re-replacement. Univariate Cox regression revealed patient age (p = 0.018), body surface area (p = 0.004), internal valve diameter (p = 0.005), and prosthesis z-score (p = 0.018) to impact valve longevity. Multivariate Cox regression analysis, however, did not show any significant effect (likely related to multicollinearity). Subgroup analysis showed that valve-revised patients have a higher average z-score (p = 0.003) and younger average age (p = 0.007). Conclusion A decreased longevity of biological valves in the pulmonary position is related to younger age, lower valve diameter, and higher z-score. Because valve size (diameter and z-score) can be predicted by age, patient age is the crucial parameter influencing graft longevity.

24 October 2026 in Children
Verified
Journal Article
Open access
PDF file
JGJulian Christoph Gerwers
Julian Christoph Gerwers
IHIda Hüners
Ida Hüners
MMMartin Munz
Martin Munz
HCHenning Carstens
Henning Carstens
JOJakob Olfe
Jakob Olfe
DBDaniel Biermann
Daniel Biermann
Aorto-left ventricular tunnel (ALVT) is a rare congenital extracardiac communication between the ascending aorta and the left ventricle (LV) that originates above the aortic valve leaflets; approximately 177 cases have been published. We report an 11-month-old boy referred after a “to-and-fro” murmur was detected on routine examination. External transthoracic echocardiography (TTE) had suggested a subpulmonary ventricular septal defect (VSD) with an aneurysm of the right ventricular outflow tract (RVOT). At our institution, TTE showed a dilated LV (z-score +4.2) with preserved ejection fraction (EF, approximately 60%) and a tunnel with predominantly diastolic flow from the ascending aorta into the LV. Computed tomography angiography (CTA) with 3D reconstruction confirmed a Hovaguimian type II ALVT whose aortic orifice lies approximately 8 mm craniodorsal of the right coronary artery (RCA) ostium, without communication with the RCA or the RVOT. Interdisciplinary Heart Team recommended surgical closure of the tunnel. The ventricular orifice was closed with a patch and the aortic orifice by direct suture; the RCA ostium and the aortic valve were confirmed intraoperatively not to be compromised. Transient postoperative LV systolic dysfunction (EF 28%) resolved by postoperative day five. At fifteen-month follow-up, LV size and function were normal, aortic regurgitation was minimal, and there was no residual tunnel flow. Multimodality imaging that defined the coronary relationship enabled a repair preserving both the RCA and the aortic valve.

26 September 2026 in Children
Verified
Journal Article
Open access
PDF file
IHIda Hüners
Ida Hüners
SSSophia Schumann
Sophia Schumann
GSGerhard Schön
Gerhard Schön
DBDaniel Biermann
Daniel Biermann
JDJonas DENECKE
Jonas DENECKE
SHSebastian H. Harms
Sebastian H. Harms
Background/Objectives: Iatrogenic withdrawal syndrome (IWS) is common but underrecognized in critically ill children, and data from pediatric cardiac intensive care units (pCICUs) remain limited. This study determined the frequency of IWS after cardiac surgery and the factors associated with it. Methods: Retrospective, single-center cohort study of all pediatric patients admitted to a pCICU after cardiac surgery over 15 months. IWS screening was performed using the Withdrawal Assessment Tool-1 (WAT-1) at least three times daily post-extubation. IWS was defined as at least one WAT-1 score of 3 or higher. A prespecified multivariable logistic regression model with ten perioperative variables was fitted in the complete-case population. A subgroup analysis in ventilated children examined sedative and analgesic exposure, including the grouped duration of remifentanil infusion, in an adjusted model. Results: Of 311 patients, 294 (94.5%) were screened, and IWS occurred in 136 patients (46.3%, 95% CI 40.6–52.0). In the complete-case population (n = 286), univentricular physiology (OR 2.51, p = 0.044), suspected postoperative infection (OR 5.28, p = 0.023), and invasive ventilation for 10–100 h (OR 2.75, p = 0.021) or beyond 100 h (OR 5.29, p = 0.003) were independently associated with IWS, whereas postoperative lactatemia (>2 mmol/L for >6 h) was associated with lower odds (OR 0.39, p = 0.039). In mechanically ventilated children (n = 162), after adjustment, no sedative or analgesic exposure was significantly associated with IWS, while odds were substantially higher in patients receiving remifentanil beyond 48 h (OR 2.64, p = 0.114) and midazolam (OR 3.95, p = 0.057). Conclusions: In our institution, IWS was highly frequent after pediatric cardiac surgery, in particular in patients with univentricular physiology. In sedated patients, midazolam and prolonged remifentanil showed substantially higher, though not statistically significant, odds of developing IWS. These hypothesis-generating associations require prospective confirmation.